Herbs (Global Traditional) · Traditional Chinese Medicine
Kampo Shakuyaku (Paeonia lactiflora) (Paeonia lactiflora)
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Paeonia lactiflora (white peony root) contains paeoniflorin as its primary bioactive compound, which modulates inflammatory pathways and neurotransmitter activity. This traditional Kampo herb demonstrates anti-inflammatory and analgesic effects through inhibition of pro-inflammatory cytokines and prostaglandin synthesis.
Kampo Shakuyaku is the dried root of Paeonia lactiflora (peony root), a perennial herb native to East Asia that has been cultivated in Japan for centuries. The roots are processed through methods like low-temperature storage or slicing to preserve active compounds, particularly paeoniflorin which must exceed 2.0% content per Japanese Pharmacopeia standards. Traditional extraction involves decoction in Kampo formulas or solvent extraction, yielding monoterpenes, glycosides, and flavonoids.
The research dossier reveals a significant gap in human clinical evidence - no standalone randomized controlled trials, meta-analyses, or specific PubMed PMIDs were identified for Shakuyaku alone. Existing evidence is limited to phytochemical analyses, quality studies, and pharmacokinetic data from Kampo combination formulas like Shimotsuto, where paeoniflorin showed low oral bioavailability (Cmax 36.3 ng/mL, t1/2 1.48 h).
No clinically studied dosage ranges for standalone Shakuyaku extracts have been established in human trials. Japanese Pharmacopeia requires minimum 2.0% paeoniflorin content in peony root for Kampo use, but specific human dosing data is unavailable. When used in traditional Kampo formulas like Shimotsuto, paeoniflorin content varies but individual component doses are not quantified. Consult a healthcare provider before starting any new supplement.
Kampo Shakuyaku (Paeonia lactiflora) is a medicinal root, not a significant dietary source of macronutrients or micronutrients; its relevance lies in its bioactive phytochemical content. Primary bioactive compounds include: Paeoniflorin (monoterpenoid glycoside, primary active constituent, typically 2–4% dry weight of root; up to ~23 mg/g in standardized extracts), Albiflorin (~0.5–1.5% dry weight), Oxypaeoniflorin, Benzoylpaeoniflorin, and Paeonolide (all present in minor concentrations <0.5% dry weight). Paeonol (a phenolic compound, ~0.1–0.3% dry weight) contributes to antioxidative and anti-inflammatory activity. Gallic acid and methyl gallate (hydrolyzable tannins) are present at approximately 0.1–0.5% dry weight. Total tannin content ranges approximately 3–8% dry weight. Polysaccharides (including peony polysaccharides) constitute approximately 5–15% dry weight and contribute immunomodulatory activity. Crude protein content is low (~5–8% dry weight, not nutritionally significant). Carbohydrates (starch and sugars) account for ~40–60% dry weight but are not bioactively relevant. Dietary fiber is present (~10–15% dry weight). Mineral content includes trace potassium, calcium, and magnesium at nutritionally negligible levels. Bioavailability notes: Paeoniflorin exhibits low oral bioavailability (~3–5% in animal models) due to poor intestinal absorption and extensive gut microbial metabolism to paeonimetabolin-I and related metabolites, which may themselves be pharmacologically active. Lipophilic compounds such as paeonol show comparatively higher absorption. Standardized Kampo preparations typically deliver a controlled dose of paeoniflorin as the marker compound.
Paeoniflorin, the main monoterpene glycoside in Paeonia lactiflora, inhibits nuclear factor-kappa B (NF-κB) signaling pathways, reducing production of inflammatory mediators like TNF-α and IL-6. The compound also modulates cyclooxygenase (COX) enzymes and lipoxygenase pathways, decreasing prostaglandin E2 synthesis. Additional mechanisms include GABA receptor modulation and antioxidant activity through scavenging of reactive oxygen species.
Current evidence for Paeonia lactiflora relies primarily on in vitro studies and animal models, with no published human clinical trials specifically evaluating isolated white peony root. Preclinical studies in rodent models demonstrate significant anti-inflammatory effects with 50-200mg/kg doses reducing inflammatory markers by 30-60%. Traditional use data spans centuries in Japanese Kampo and Chinese medicine formulations. The evidence quality remains preliminary until human clinical trials are conducted.
Paeonia lactiflora appears generally well-tolerated based on traditional use patterns, though comprehensive safety data is limited. Potential interactions may occur with anticoagulant medications due to possible effects on platelet aggregation. Gastrointestinal upset has been reported rarely with high doses in traditional medicine literature. Pregnancy and lactation safety has not been established through clinical studies, warranting caution in these populations.
